Por favor, use este identificador para citar o enlazar a este item:
http://hdl.handle.net/10261/288024
COMPARTIR / EXPORTAR:
SHARE CORE BASE | |
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL | DATACITE | |
Título: | Cell-Free DNA as a Prognostic Biomarker for Monitoring Muscle-Invasive Bladder Cancer |
Autor: | Carrasco, Raquel; Ingelmo-Torres, Mercedes; Gómez, Ascención; Trullas, Ramón CSIC ORCID; Roldán, Fiorella L.; Ajami, Tarek; Moreno, Davinia; Rodríguez-Carunchio, Leonardo; Alcaraz, Antonio; Izquierdo, Laura; Mengual, Lourdes | Palabras clave: | Bladder cancer Cell-free DNA Circulating tumor DNA Droplet digital PCR Prognosis |
Fecha de publicación: | 3-oct-2022 | Editor: | Molecular Diversity Preservation International | Citación: | International Journal of Molecular Sciences 23(19): 11732 (2022) | Resumen: | Cell-free DNA (cfDNA) has recently emerged as a real-time biomarker for diagnosis, monitoring and prediction of therapy response in tumoral disease. Here, we evaluated cfDNA as a prognostic biomarker for monitoring muscle-invasive bladder cancer (MIBC) patients at different follow-up time points. Blood samples from 37 MIBC patients who underwent radical cystectomy (RC) were collected at cystectomy and 1, 4, 12 and 24 months later. Plasma cfDNA amount and fragmentation patterns were determined. Four mutations were analyzed in cfDNA to detect circulating tumor DNA (ctDNA) during patient follow-up. During a median follow-up of 36 months, 46% of patients progressed; median time to progression was 10 months. cfDNA levels and ctDNA status four months after RC were identified as independent prognostic biomarkers of tumor progression (HR 5.290; p = 0.033) and cancer-specific survival (HR 4.199; p = 0.038), respectively. Furthermore, ctDNA clearance four months after RC was significantly associated with patients’ clinical outcomes. In conclusion, cfDNA levels and ctDNA status four months after RC have prognostic implications in MIBC patients. In addition, cfDNA monitoring is useful to predict patient outcomes after RC. cfDNA analysis in the clinical setting could greatly improve MIBC patient management. | Versión del editor: | http://dx.doi.org/10.3390/ijms231911732 | URI: | http://hdl.handle.net/10261/288024 | DOI: | 10.3390/ijms231911732 | Identificadores: | doi: 10.3390/ijms231911732 issn: 1422-0067 e-issn: 1661-6596 |
Aparece en las colecciones: | (IIBB) Artículos |
Ficheros en este ítem:
Fichero | Descripción | Tamaño | Formato | |
---|---|---|---|---|
ijms-23-11732-v3.pdf | 1,74 MB | Adobe PDF | Visualizar/Abrir |
CORE Recommender
SCOPUSTM
Citations
7
checked on 22-abr-2024
WEB OF SCIENCETM
Citations
4
checked on 28-feb-2024
Page view(s)
39
checked on 27-abr-2024
Download(s)
46
checked on 27-abr-2024
Google ScholarTM
Check
Altmetric
Altmetric
Este item está licenciado bajo una Licencia Creative Commons